PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Semaglutide

NN9535; Ozempic; Wegovy; Rybelsus

Classification: GLP-1 receptor agonist

Mechanism: GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion

Benefits: Weight loss ~15% (STEP); HbA1c reduction; cardiovascular protection (SELECT); appetite control

Evidence tier: FDA-Approved · Availability: Prescription

Primary sources

  1. FDA Wegovy (semaglutide) prescribing information
  2. FDA Ozempic (semaglutide) prescribing information
  3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021. PMID 33567185
  4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023. PMID 37952131

Loading interactive view…